MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by AIM ImmunoTech Inc.

< Previous 1 2 3 4 5 6 Next >
News headline image
AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
From AIM ImmunoTech Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story